Kirn David sold $737K of FDMT
Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.64 ($12.01–$12.87, $0.74M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, share count, price range, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Insider selling disclosures can influence short-term sentiment, but 10b5-1 context typically reduces interpretive weight.
What to watch
Traders may watch for clustering of insider sales across multiple officers or repeated filings after the plan window, which could matter more than a single transaction.
Background
The article is an SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
Kirn David, an FDMT officer/director, sold $737,410 of FDMT shares in open-market trades under a pre-arranged 10b5-1 plan.
Likely limited, short-lived impact unless follow-on selling appears in subsequent filings.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific fundamentals.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may not reflect bearish expectations and could be largely informational noise.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderKirn David
Officer and director who sold shares under a 10b5-1 plan.
